ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
In vitro and in vivo antibacterial activity of oral tebipenem in combination with novel β-lactamase inhibitors (avibactam, relebactam, vaborbactam) against KPC-producing Enterobacterales.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeCarbapenem-resistant Enterobacterales (CRE) pose a severe and growing threat to global public health, with limited clinically available therapeutic options. This study aimed to evaluate the antibacterial efficacy of tebipenem (TEB) combined with the novel β-lactamase inhibitors avibactam, relebactam, and vaborbactam, both in vitro and in vivo, against a panel of 77 clinical isolates of KPC-producing Enterobacterales.
methodsThe MICs of ceftazidime-avibactam (CAZ-AVI), TEB, TEB-avibactam (TEB-AVI), TEB-relebactam (TEB-REL), and TEB-vaborbactam (TEB-VAB) were determined using the broth microdilution method. Time-kill assays, biofilm formation tests, Galleria mellonella assays, and scanning electron microscopy imaging were employed to assess the antibacterial activity of the combination of TEB and new β-lactamase inhibitors (AVI, REL, and VAB) against KPC-producing Enterobacterales isolates in vitro and in vivo. PCR and Sanger sequencing were used to identify carbapenemase genes.
resultsAntimicrobial susceptibility testing revealed that the majority of isolates exhibited high resistance to TEB, with 90.9% (70/77) exhibiting MIC values of ≥ 64 µg/mL. Among the single KPC-producers (n = 77), the combination of TEB with either avibactam (AVI) or vaborbactam (VAB) significantly reduced the TEB MIC₅₀/MIC₉₀ values from > 64/>64 µg/mL to 1/4 µg/mL, respectively. Notably, the antibacterial efficacy of TEB-AVI combinations was comparable to that of ceftazidime-avibactam (CAZ-AVI), which exhibited MIC₅₀/MIC₉₀ values of 2/4 µg/mL. Similarly, TEB combined with relebactam (REL) led to a significant reduction in TEB MIC₅₀/MIC₉₀ values, decreasing from > 64/>64 µg/mL to 2/4 µg/mL, respectively. Furthermore, the MIC values of TEB-AVI, TEB-REL, and TEB-VAB against the CAZ-AVI-resistant isolate harboring bla
conclusionThe combinations of oral TEB and novel β-lactamase inhibitors exhibit a potent antibacterial activity against KPC-producing Enterobacterales isolates in vitro and in vivo. Their potency is comparable to that of CAZ-AVI, and they even demonstrate potential efficacy against CAZ-AVI-resistant isolates. These findings provide a theoretical basis for the clinical management of CRE infections. Additionally, this combination serves as a viable step-down therapeutic option potentially facilitating earlier hospital discharge.
Indexed as
Identifiers
42165965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.